Generic placeholder image

Current Drug Therapy

Author(s): Sergey Yu. Martsevich, Yulia V. Lukina, Olga V. Lerman, Natalia P. Kutishenko, Anton R. Kiselev* and Oxana M. Drapkina

DOI: 10.2174/0115748855261762231011050708

DownloadDownload PDF Flyer Cite As
Self-awareness Regarding Obesity and Specific Therapy in Patients with Overweight or Obesity and Cardiovascular Diseases from Moscow Region

Page: [821 - 827] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Objectives: Despite the proven effectiveness of lifestyle interventions and specific medications in the treatment of obesity, little is known about their use in real-world practice. Aims: To study the awareness of patients about the problem of overweight/obesity, as well as the clinical practice of non-drug and drug therapy according to the survey.

Materials and Methods: Eligible patients were recruited from the prospective outpatient registry of patients with cardiovascular diseases. The design of the study was a cross-sectional cohort singlecentre. All of the included patients completed a specifically designed questionnaire. The study included 295 patients (mean age 66.8 ± 11.8 years) with a body mass index (BMI) of ≥ 25 kg/m2. One hundred eight (36.6%) individuals were overweight, 124 (42.2%) had first-class obesity, 42 (14.2%) had second-class obesity, and 21 (7.1%) patients had third-class obesity.

Results: 252 patients (85.4%) were informed of being overweight/obese, and all of them received non-drug recommendations for the treatment of obesity. Anti-obesity medications (AOM) were recommended only to 25 (8.5%) patients: 3 – overweight, 11 – obesity class I, 6 obesity class II, and 5 – obesity class III. Twenty-one (7.1%) patients took the prescribed medications (84% adherence). The drugs were more often taken by patients with class II and III disease (40.5% and 57.1% of patients, respectively). Overweight (8.5%) and class I obesity (18.0%) patients took these drugs less often (p < 0.0001).

Conclusion: The results of the survey have demonstrated good awareness of patients about their obesity/overweight and quite frequent use of non-drug obesity therapy. However, the rate of AOM prescription was extremely low.

Graphical Abstract

[1]
World Health Organization. Prevalence of obesity among adults, BMI ≥ 30, age-standardized Estimates by WHO region. 2017. Available from: http://apps.who.int/gho/data/view.main.REGION 2480A?lang=en/ (accessed 8 July 2021)
[2]
Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi’i A. A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med 2021; 136: 104754.
[http://dx.doi.org/10.1016/j.compbiomed.2021.104754] [PMID: 34426171]
[3]
Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: A scientific statement from the american heart association. Circulation 2021; 143(21): e984-e1010.
[http://dx.doi.org/10.1161/CIR.0000000000000973] [PMID: 33882682]
[4]
American Medical Association. AMA adopts new policies on second day of voting at annual meeting. 2013. Available from: http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18- new-ama-policies-annual-meeting.page/ (accessed 8 July 2021)
[5]
Puhl RM, Liu S. A national survey of public views about the classification of obesity as a disease. Obesity 2015; 23(6): 1288-95.
[http://dx.doi.org/10.1002/oby.21068] [PMID: 25970728]
[6]
World Health Organization. Obesity and overweight. 2018. Available from: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight/ (accessed 8 July 2021)
[7]
Curry SJ, Krist AH, Owens DK, et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement. JAMA 2018; 320(11): 1163.
[http://dx.doi.org/10.1001/jama.2018.13022]
[8]
Dedov II, Mel’nichenko GA, Shestakova MV, et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obes Metab 2018; 15(1): 53-70.
[http://dx.doi.org/10.14341/omet2018153-70]
[9]
Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts 2015; 8(6): 402-24.
[http://dx.doi.org/10.1159/000442721] [PMID: 26641646]
[10]
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the american college of cardiology/american heart association task force on practice guidelines and the obesity society. Circulation 2014; 129: S102-38.
[http://dx.doi.org/10.1161/01.cir.0000437739.71477.ee] [PMID: 24222017]
[11]
Haire-Joshu D, Hill-Briggs F. Treating obesity-moving from recommendation to implementation. JAMA Intern Med 2018; 178(11): 1447-9.
[http://dx.doi.org/10.1001/jamainternmed.2018.5259] [PMID: 30422261]
[12]
Martsevich SY, Lukina YV, Lerman OV, Kutishenko NP, Semenova YV. Obesity treatment and adherence to doctors′ recommendations in patients with cardiovascular diseases and/or cardiovascular disease risk factors (results of patients’ interviews within the outpatient registry «PROFILE»). Obes Med 2019; 15: 100119.
[http://dx.doi.org/10.1016/j.obmed.2019.100119]
[13]
World Health Organization. Body mass index - BMI. Available from: https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi/ (accessed 8 July 2021)
[14]
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: A systematic and clinical review. J Amer Med Assoc 2014; 311: 74-86.
[http://dx.doi.org/10.1001/jama.2013.281361]
[15]
LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality 2018.
[16]
Farrell E, Hollmann E, le Roux CW, Bustillo M, Nadglowski J, McGillicuddy D. The lived experience of patients with obesity: A systematic review and qualitative synthesis. Obes Rev 2021; 22(12): e13334.
[http://dx.doi.org/10.1111/obr.13334] [PMID: 34402150]
[17]
Xia Y, Kelton CML, Guo JJ, Bian B, Heaton PC. Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010. Obesity 2015; 23(8): 1721-8.
[http://dx.doi.org/10.1002/oby.21136] [PMID: 26193062]
[18]
Simon R, Lahiri SW. Provider practice habits and barriers to care in obesity management in a large multicenter health system. Endocr Pract 2018; 24(4): 321-8.
[http://dx.doi.org/10.4158/EP-2017-0221] [PMID: 29561192]
[19]
Bleich SN, Bennett WL, Gudzune KA, Cooper LA. National survey of US primary care physicians’ perspectives about causes of obesity and solutions to improve care. BMJ Open 2012; 2(6): e001871.
[http://dx.doi.org/10.1136/bmjopen-2012-001871] [PMID: 23257776]
[20]
Doyle S, Lloyd A, Birt J, et al. Willingness to pay for obesity pharmacotherapy. Obesity 2012; 20(10): 2019-26.
[http://dx.doi.org/10.1038/oby.2011.387] [PMID: 22301901]
[21]
Shahed Q, Baranowska K, Galavazi MC, Cao Y, van Nieuwenhoven MA. Doctors and patients’ perspectives on obesity. A Q-methodology study. Fam Pract 2022; 39(4): 694-700.
[http://dx.doi.org/10.1093/fampra/cmab169] [PMID: 35022704]